Up next

Company Executives Outline Growth Strategies and Expansions at the DCAT Member Company Announcement Forum

In this special issue of DCAT Value Chain Insights, we are providing information that would have been presented at the DCAT Member Company Announcement Forum at DCAT Week ’20. Originally scheduled to be held on March 23 in New York, these announcements were selected by the Announcement Oversight Task Force, as they present the latest major company news impacting the pharmaceutical manufacturing value chain. CEOs and senior executives from DCAT member companies outline their companies’ growth strategies by providing updates on key mergers and acquisitions and expansions with news from the following companies: Cambrex, Recipharm, Thermo Fisher Scientific, Lonza, SK pharmteco, Catalent, Biocon, CordenPharma, and WuXi STA. The individual news developments are outlined below.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

Innovation & Pharma: The Molecules & Companies

By
How truly innovative is the bio/pharma industry? What products, modalities, and companies are behind that innovation? Looking at “first-in-class” new drug approvals, defined as drugs with new mechanisms of action over existing drugs, reveals an interesting picture.

FDA Launches Pilot To Expedite INDs

By
FDA has launched a pilot program to expedite review of investigational new drug (IND) filings with applications for the pilot due by October 30. It is part of the agency’s Operation TrialBlazer initiative, designed to make the US more competitive in early-stage research.

Beyond ADCs: Next-Generation Drug Conjugates 

By
Antibody drug conjugates (ADCs) continue to be a strong growth area, but next-generation drug conjugates, encompassing oligonucleotides, peptides, and other small-molecule payloads, are on the rise.

Sandoz Maps Out Ambitious Biosimilars Growth Plan

By
Sandoz has rolled out a plan to increase its biosimilars portfolio to more than 100 biosimilars, including generic GLP-1’s by 2040, increase manufacturing capacity, and more than double its net sales by 2035.